{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:52:31Z","timestamp":1792453951849,"version":"4.5.0"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T00:00:00Z","timestamp":1644192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","award":["116:105615"],"award-info":[{"award-number":["116:105615"]}],"id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","award":["122:105734"],"award-info":[{"award-number":["122:105734"]}],"id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","award":["122:105739"],"award-info":[{"award-number":["122:105739"]}],"id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","award":["33501756"],"award-info":[{"award-number":["33501756"]}],"id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","award":["79:308\u2013317"],"award-info":[{"award-number":["79:308\u2013317"]}],"id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","award":["842:89\u201398"],"award-info":[{"award-number":["842:89\u201398"]}],"id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","award":["85:149\u2013158"],"award-info":[{"award-number":["85:149\u2013158"]}],"id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","award":["898:173983"],"award-info":[{"award-number":["898:173983"]}],"id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","award":["BKM120"],"award-info":[{"award-number":["BKM120"]}],"id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","award":["CAL-101"],"award-info":[{"award-number":["CAL-101"]}],"id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.tranon.2022.101364","type":"journal-article","created":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:33:54Z","timestamp":1644626034000},"page":"101364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":187,"special_numbering":"C","title":["The PI3K\/Akt\/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles"],"prefix":"10.1016","volume":"18","author":[{"given":"Mohammad-Javad","family":"Sanaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Razi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atieh","family":"Pourbagheri-Sigaroodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-4920","authenticated-orcid":false,"given":"Davood","family":"Bashash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2022.101364_bib0001","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1158\/1078-0432.CCR-17-2289","article-title":"The impact of smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations-the Lung Cancer mutation consortium (LCMC2)","volume":"24","author":"Aisner","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccm.2019.10.001","article-title":"Lung Cancer 2020: epidemiology, etiology, and prevention","volume":"41","author":"Bade","year":"2020","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.tranon.2022.101364_bib0003","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/jcp.25426","article-title":"Ginkgolic acid inhibits invasion and migration and TGF-\u03b2-induced EMT of Lung Cancer cells through PI3K\/Akt\/mTOR inactivation","volume":"232","author":"Baek","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.tranon.2022.101364_bib0004","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/carcin\/bgh226","article-title":"Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions","volume":"25","author":"Balsara","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.tranon.2022.101364_bib0005","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/1078-0432.CCR-17-2260","article-title":"A phase I open-label study to identify a dosing regimen of the Pan-AKT inhibitor AZD5363 for evaluation in solid tumors and in PIK3CA-mutated breast and gynecologic cancers","volume":"24","author":"Banerji","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0006","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","article-title":"Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors","volume":"30","author":"Bendell","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0007","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/jco.2011.29.15_suppl.3044","article-title":"A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC)","volume":"29","author":"Besse","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-5231(03)00057-1","article-title":"Epidemiology, etiology, and prevention of lung cancer","volume":"23","author":"Bilello","year":"2002","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.tranon.2022.101364_bib0009","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1158\/1535-7163.MCT-17-0464","article-title":"RAS\u2013MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR\u2013MEK blockade","volume":"17","author":"Bockorny","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2022.101364_bib0010","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1158\/1078-0432.CCR-0629-3","article-title":"Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer","volume":"10","author":"Boffa","year":"2004","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0011","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/ncb2396","article-title":"Reprogramming of the tumour microenvironment by stromal PTEN-regulated miR-320","volume":"14","author":"Bronisz","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.tranon.2022.101364_bib0012","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","article-title":"Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor","volume":"96","author":"Brunet","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2022.101364_bib0013","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11033-011-0724-3","article-title":"Rapamycin decreases survivin expression to induce NSCLC cell apoptosis under hypoxia through inhibiting HIF-1\u03b1 induction","volume":"39","author":"Chen","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.tranon.2022.101364_bib0014","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1007\/s11033-011-1128-0","article-title":"Transforming growth factor-\u03b21 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K\/Akt and MEK\/Erk1\/2 signaling pathways","volume":"39","author":"Chen","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.tranon.2022.101364_bib0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2217\/lmt.13.72","article-title":"Targeting the PI3K\/AKT\/mTOR pathway: potential for lung cancer treatment","volume":"3","author":"Cheng","year":"2014","journal-title":"Lung Cancer Manag."},{"key":"10.1016\/j.tranon.2022.101364_bib0016","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/ijc.25134","article-title":"MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K\/AKT signaling in A549 lung cancer cells","volume":"127","author":"Chetty","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tranon.2022.101364_bib0017","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/carcin\/bgx054","article-title":"Melatonin as a promising agent to treat ovarian cancer: molecular mechanisms","volume":"38","author":"Chuffa","year":"2017","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.tranon.2022.101364_bib0018","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1242\/dmm.004077","article-title":"Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer","volume":"4","author":"Cox","year":"2011","journal-title":"Dis. Models Mech."},{"key":"10.1016\/j.tranon.2022.101364_bib0019","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1158\/1078-0432.CCR-08-1253","article-title":"Mechanism and management of AKT inhibitor-induced hyperglycemia","volume":"15","author":"Crouthamel","year":"2009","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0020","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccm.2011.09.001","article-title":"Lung cancer: epidemiology, etiology, and prevention","volume":"32","author":"Cruz","year":"2011","journal-title":"Clin. Chest Med."},{"key":"10.1016\/j.tranon.2022.101364_bib0021","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.pharmthera.2019.02.010","article-title":"Nanotechnology in the diagnosis and treatment of lung cancer","volume":"198","author":"Cryer","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tranon.2022.101364_bib0022","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc1819","article-title":"Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis","volume":"6","author":"Cully","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tranon.2022.101364_bib0023","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1470-2045(17)30688-5","article-title":"Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Di Leo","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0024","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hep.30818","volume":"71","author":"Dimri","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.tranon.2022.101364_bib0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-0500-1-14","article-title":"Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting","volume":"1","author":"Do","year":"2008","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.tranon.2022.101364_bib0026","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/onc.2014.164","article-title":"mTORC1 drives HIF-1\u03b1 and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3","volume":"34","author":"Dodd","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2022.101364_bib0027","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1188\/20.CJON.673-680","article-title":"PI3K inhibitors and adverse events: optimizing patient care for the treatment of advanced breast cancer","volume":"24","author":"Donahue","year":"2020","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.tranon.2022.101364_bib0028","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1535-7163.MCT-07-0004","article-title":"The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway","volume":"6","author":"Elrod","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2022.101364_bib0029","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1172\/JCI28656","article-title":"Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer","volume":"116","author":"Engelman","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tranon.2022.101364_bib0030","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cmet.2018.12.020","article-title":"Loss of BCAA catabolism during carcinogenesis enhances mTORC1 activity and promotes tumor development and progression","volume":"29","author":"Ericksen","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.tranon.2022.101364_bib0031","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.addr.2010.04.009","article-title":"The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect","volume":"63","author":"Fang","year":"2011","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"10.1016\/j.tranon.2022.101364_bib0032","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.biocel.2016.06.023","article-title":"Inhibition of autophagy enhances effects of PF-04691502 on apoptosis and DNA damage of lung cancer cells","volume":"78","author":"Fei","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.tranon.2022.101364_bib0033","doi-asserted-by":"crossref","first-page":"11381","DOI":"10.1073\/pnas.0906461107","article-title":"Activity of any class IA PI3K isoform can sustain cell proliferation and survival","volume":"107","author":"Foukas","year":"2010","journal-title":"Proc. Nat. Acad. Sci. USA."},{"key":"10.1016\/j.tranon.2022.101364_bib0034","doi-asserted-by":"crossref","DOI":"10.1042\/BST20190845","article-title":"Class IA PI3K regulatory subunits: p110-independent roles and structures","author":"Fox","year":"2020","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.tranon.2022.101364_bib0035","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2003.07.007","article-title":"PI3K\/Akt signalling pathway and cancer","volume":"30","author":"Fresno Vara","year":"2004","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.tranon.2022.101364_bib0036","doi-asserted-by":"crossref","first-page":"8967","DOI":"10.1158\/0008-5472.CAN-09-2190","article-title":"Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy","volume":"69","author":"Fu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0037","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bcp.2014.05.011","article-title":"Targeting PI3K\/AKT\/mTOR pathway in non small cell lung cancer","volume":"90","author":"Fumarola","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tranon.2022.101364_bib0038","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.3390\/cancers11081141","article-title":"PTEN in lung cancer: dealing with the problem, building on new knowledge and turning the game around","volume":"11","author":"Gkountakos","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2022.101364_bib0039","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0140-6736(10)62101-0","article-title":"Non-small-cell lung cancer","volume":"378","author":"Goldstraw","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2022.101364_bib0040","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.canlet.2011.07.002","article-title":"Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer","volume":"310","author":"Gorzalczany","year":"2011","journal-title":"Cancer Lett."},{"issue":"14","key":"10.1016\/j.tranon.2022.101364_bib0041","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1158\/1078-0432.CCR-19-3324","article-title":"Genetic alterations in the PI3K\/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts","volume":"26","author":"Gris-Oliver","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0042","unstructured":"Guo, S. T. (2017). THE ROLE OF INOSITOL POLYPHOSPHATE 4-PHOSPHATASE II (INPP4B) IN THE PATHOGENESIS OF COLON CANCER (Doctoral dissertation, The University of Newcastle Australia)."},{"key":"10.1016\/j.tranon.2022.101364_bib0043","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1158\/1541-7786.MCR-12-0558","article-title":"Molecular dissection of AKT activation in lung cancer cell lines","volume":"11","author":"Guo","year":"2013","journal-title":"Mol. Cancer Res. MCR"},{"key":"10.1016\/j.tranon.2022.101364_bib0044","first-page":"615","article-title":"The mTOR inhibitor deforolimus is efficacious in models of mutant KRAS lung cancer","volume":"69","author":"Haines","year":"2009","journal-title":"Am. Assoc. Cancer. Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0045","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.2174\/1568026619666190902150555","article-title":"Drug combinatorial therapies for the treatment of KRAS mutated lung cancers","volume":"19","author":"He","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.tranon.2022.101364_bib0046","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ctrv.2013.08.006","article-title":"Strategies for co-targeting the PI3K\/AKT\/mTOR pathway in NSCLC","volume":"40","author":"Heavey","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.tranon.2022.101364_bib0047","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2022.101364_bib0048","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-3-662-49651-0_5","article-title":"Personalized radiation oncology: epidermal growth factor receptor and other receptor tyrosine kinase inhibitors","volume":"198","author":"Higgins","year":"2016","journal-title":"Mol. Radio Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0049","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0959-8049(97)89020-X","article-title":"D-21266, a new heterocyclic alkylphospholipid with antitumour activity","volume":"33","author":"Hilgard","year":"1997","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tranon.2022.101364_bib0050","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","article-title":"MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo","volume":"9","author":"Hirai","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2022.101364_bib0051","first-page":"2293","article-title":"Suppression of lung cancer progression by biocompatible glycerol triacrylate-spermine-mediated delivery of shAkt1","volume":"7","author":"Hong","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.tranon.2022.101364_bib0052","first-page":"2015","article-title":"Dual expression of shAkt1 and Pdcd4 suppresses lung tumorigenesis in K-rasLA1 mice","volume":"35","author":"Hong","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0053","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1158\/1535-7163.763.3.7","article-title":"Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling","volume":"3","author":"Ihle","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2022.101364_bib0054","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccr.2009.10.016","article-title":"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation","volume":"16","author":"Jaiswal","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2022.101364_bib0055","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/JTO.0000000000000088","article-title":"Phase I safety and pharmacokinetic study of the PI3K\/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors","volume":"9","author":"J\u00e4nne","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0056","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jbior.2019.03.003","article-title":"Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship","volume":"72","author":"Jhanwar-Uniyal","year":"2019","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.tranon.2022.101364_bib0057","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0065-230X(09)02002-8","article-title":"PI3K\/PTEN signaling in angiogenesis and tumorigenesis","volume":"102","author":"Jiang","year":"2009","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0058","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/mto.2016.18","article-title":"Curcumin inhibited HGF-induced EMT and angiogenesis through regulating c-Met dependent PI3K\/Akt\/mTOR signaling pathways in lung cancer","volume":"3","author":"Jiao","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.tranon.2022.101364_bib0059","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/jco.2010.28.15_suppl.3089","article-title":"Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase","volume":"28","author":"Jimeno","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0060","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.bbrc.2014.01.086","article-title":"Blockage of stat3 enhances the sensitivity of NSCLC cells to PI3K\/mTOR inhibition","volume":"444","author":"Jin","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tranon.2022.101364_bib0061","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41556-019-0291-8","article-title":"Apical\u2013basal polarity inhibits epithelial-mesenchymal transition and tumour metastasis by PAR-complex-mediated SNAI1 degradation","volume":"21","author":"Jung","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.tranon.2022.101364_bib0062","doi-asserted-by":"crossref","first-page":"eaaq1093","DOI":"10.1126\/scitranslmed.aaq1093","article-title":"PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells","volume":"10","author":"Kauko","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tranon.2022.101364_bib0063","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.lungcan.2007.06.020","article-title":"PIK3CA gene amplification in Japanese non-small cell lung cancer","volume":"58","author":"Kawano","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2022.101364_bib0064","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1183\/16000617.0071-2015","article-title":"KRAS oncogene in lung cancer: focus on molecularly driven clinical trials","volume":"25","author":"Kempf","year":"2016","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.tranon.2022.101364_bib0065","doi-asserted-by":"crossref","first-page":"5800","DOI":"10.1128\/MCB.19.8.5800","article-title":"Akt\/Protein kinase B inhibits cell death by preventing the release of cytochrome c from mitochondria","volume":"19","author":"Kennedy","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.tranon.2022.101364_bib0066","article-title":"The PI3K\/Akt\/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions","author":"Khorasani","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tranon.2022.101364_bib0067","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41556-018-0205-1","article-title":"mTOR as a central hub of nutrient signalling and cell growth","volume":"21","author":"Kim","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.tranon.2022.101364_bib0068","first-page":"1093","article-title":"Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation","volume":"2","author":"Kondapaka","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2022.101364_bib0069","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0026-0495(98)90239-6","article-title":"Insulin regulates lipoprotein lipase activity in rat adipose cells via wortmannin- and rapamycin-sensitive pathways","volume":"47","author":"Kraemer","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.tranon.2022.101364_bib0070","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/1061186X.2015.1051049","article-title":"Nanocarriers for cancer-targeted drug delivery","volume":"24","author":"Kumari","year":"2016","journal-title":"J. Drug Target."},{"key":"10.1016\/j.tranon.2022.101364_bib0071","series-title":"XL765 Targets Tumor growth, survival, and Angiogenesis in Preclinical Models By Dual Inhibition of PI3K and mTOR","author":"Laird","year":"2007"},{"key":"10.1016\/j.tranon.2022.101364_bib0072","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1158\/1078-0432.CCR-14-3281","article-title":"Phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer who previously progressed on erlotinib","volume":"21","author":"Lara","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0073","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non\u2013small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0074","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-1542","article-title":"Landscape of EGFR-dependent and-independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC","volume":"24","author":"Le","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0075","doi-asserted-by":"crossref","first-page":"23874","DOI":"10.18632\/oncotarget.8074","article-title":"Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers","volume":"7","author":"Lee","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2022.101364_bib0076","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41580-018-0015-0","article-title":"The functions and regulation of the PTEN tumour suppressor: new modes and prospects","volume":"19","author":"Lee","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.tranon.2022.101364_bib0077","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1177\/0963689719885083","article-title":"PRMT5 promotes human lung cancer cell apoptosis via Akt\/Gsk3\u03b2 signaling induced by resveratrol","volume":"28","author":"Li","year":"2019","journal-title":"Cell Transplant."},{"key":"10.1016\/j.tranon.2022.101364_bib0078","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41388-018-0479-6","article-title":"mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer","volume":"38","author":"Liang","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2022.101364_bib0079","first-page":"853","article-title":"PTEN and phosphorylated AKT expression and prognosis in early- and late-stage non-small cell lung cancer","volume":"17","author":"Lim","year":"2007","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.tranon.2022.101364_bib0080","first-page":"1523","article-title":"Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K\/Akt\/mTOR pathway","volume":"39","author":"Liu","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.tranon.2022.101364_bib0081","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3390\/ijms18020367","article-title":"Role of autophagy and apoptosis in non-small-cell lung cancer","volume":"18","author":"Liu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2022.101364_bib0082","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/CAD.0000000000000117","article-title":"FOXO3a mediates the cytotoxic effects of cisplatin in lung cancer cells","volume":"25","author":"Liu","year":"2014","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.tranon.2022.101364_bib0083","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2217\/fon-2017-0588","article-title":"PI3K in cancer: Its structure, activation modes and role in shaping tumor microenvironment","volume":"14","author":"Liu","year":"2018","journal-title":"Future Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0084","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3390\/cancers11122032","article-title":"Gigantol targets cancer stem cells and destabilizes tumors via the suppression of the PI3K\/AKT and JAK\/STAT pathways in ectopic lung cancer xenografts","volume":"11","author":"Losuwannarak","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2022.101364_bib0085","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3892\/ijo.2017.3999","article-title":"MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN\/PI3K\/AKT signaling pathway in non-small cell lung cancer metastasis","volume":"51","author":"Lu","year":"2017","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0086","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2476842","article-title":"PTEN inhibits cell proliferation, promotes cell apoptosis, and induces cell cycle arrest via downregulating the PI3K\/AKT\/hTERT pathway in lung adenocarcinoma A549 cells","volume":"2016","author":"Lu","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.tranon.2022.101364_bib0087","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/JTO.0b013e31820a3a6b","article-title":"Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer","volume":"6","author":"Ludovini","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0088","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejca.2011.09.006","article-title":"The catalytic phosphoinositol 3-kinase isoform p110\u03b4 is required for glioma cell migration and invasion","volume":"48","author":"Luk","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.tranon.2022.101364_bib0089","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1080\/1061186X.2018.1542533","article-title":"A novel PI3K\/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC","volume":"27","author":"Lv","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.tranon.2022.101364_bib0090","doi-asserted-by":"crossref","first-page":"38825","DOI":"10.18632\/oncotarget.16404","article-title":"MTA1 promotes epithelial to mesenchymal transition and metastasis in non-small-cell lung cancer","volume":"8","author":"Ma","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2022.101364_bib0091","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4161\/cc.7.5.5485","article-title":"Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung","volume":"7","author":"Malanga","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.tranon.2022.101364_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2019.113729","article-title":"PI3K\/AKT\/mTOR signaling as a molecular target in head and neck cancer","volume":"172","author":"Marquard","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tranon.2022.101364_bib0093","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.humpath.2005.05.006","article-title":"PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration","volume":"36","author":"Marsit","year":"2005","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.tranon.2022.101364_bib0094","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2021.10.018","article-title":"The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle","volume":"340","author":"Masoumi","year":"2021","journal-title":"J. Controll. Release"},{"key":"10.1016\/j.tranon.2022.101364_bib0095","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1158\/1078-0432.CCR-17-0725","article-title":"A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors","volume":"23","author":"Mateo","year":"2017","journal-title":"Clin. Can. Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0096","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.3390\/ijms19123931","article-title":"Class I phosphoinositide 3-kinase PIK3CA\/p110\u03b1 and PIK3CB\/p110\u03b2 isoforms in endometrial cancer","volume":"19","author":"Mazloumi Gavgani","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2022.101364_bib0097","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1016\/j.bbamcr.2016.09.004","article-title":"Effects of mutations in Wnt\/\u03b2-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-diverse effects on cell growth, metabolism and cancer","volume":"1863","author":"McCubrey","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.tranon.2022.101364_bib0098","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.lungcan.2016.11.018","article-title":"PIK3CA mutations as prognostic factor in squamous cell lung carcinoma","volume":"103","author":"McGowan","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2022.101364_bib0099","doi-asserted-by":"crossref","first-page":"e14124","DOI":"10.1371\/journal.pone.0014124","article-title":"Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo","volume":"5","author":"Meng","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2022.101364_bib0100","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3892\/or.2012.1855","article-title":"Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells","volume":"28","author":"Miyake","year":"2012","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.tranon.2022.101364_bib0101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-8722-7-1","article-title":"Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin\/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors","volume":"7","author":"Molife","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0102","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.biopha.2016.07.043","article-title":"Rosemary extract reduces Akt\/mTOR\/p70S6K activation and inhibits proliferation and survival of A549 human lung cancer cells","volume":"83","author":"Moore","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tranon.2022.101364_bib0103","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1002\/cam4.3131","article-title":"Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment","volume":"9","author":"Nogova","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.tranon.2022.101364_bib0104","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1111\/j.1349-7006.2011.01967.x","article-title":"Inhibition of mTOR by temsirolimus contributes to prolonged survival of mice with pleural dissemination of non-small-cell lung cancer cells","volume":"102","author":"Ohara","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tranon.2022.101364_bib0105","doi-asserted-by":"crossref","first-page":"E2127","DOI":"10.1073\/pnas.1203530109","article-title":"Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1","volume":"109","author":"Ohashi","year":"2012","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"10.1016\/j.tranon.2022.101364_bib0106","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000480414","article-title":"Long noncoding RNA FAL1 promotes cell proliferation, invasion and epithelial-mesenchymal transition through the PTEN\/AKT signaling axis in non-small cell lung cancer","volume":"43","author":"Pan","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.tranon.2022.101364_bib0107","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1097\/JTO.0b013e31825493eb","article-title":"Development of PI3K\/AKT\/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer","volume":"7","author":"Papadimitrakopoulou","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0108","first-page":"749","article-title":"The Akt\/mTOR and mitogen-activated protein kinase pathways in lung cancer therapy","volume":"1","author":"Papadimitrakopoulou","year":"2006","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0109","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1097\/JTO.0b013e3182614835","article-title":"Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Papadimitrakopoulou","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2019.01.013","article-title":"PTEN inactivation induces epithelial-mesenchymal transition and metastasis by intranuclear translocation of \u03b2-catenin and snail\/slug in non-small cell lung carcinoma cells","volume":"130","author":"Perumal","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2022.101364_bib0111","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1476-4598-13-9","article-title":"A dedicated microarray for in-depth analysis of pre-mRNA splicing events: application to the study of genes involved in the response to targeted anticancer therapies","volume":"13","author":"Pesson","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tranon.2022.101364_bib0112","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1200\/jco.2011.29.15_suppl.3066","article-title":"A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors","volume":"29","author":"Peyton","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0113","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ijc.30457","article-title":"BAY 1125976, a selective allosteric AKT1\/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models","volume":"140","author":"Politz","year":"2017","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tranon.2022.101364_bib0114","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106032","article-title":"Retinoblastoma binding protein 2 (RBP2) promotes HIF-1\u03b1-VEGF-induced angiogenesis of non-small cell lung cancer via the Akt pathway","volume":"9","author":"Qi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2022.101364_bib0116","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1002\/cncr.25264","article-title":"Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent\/refractory nonsmall cell lung cancer","volume":"116","author":"Ramalingam","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2022.101364_bib0117","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1078-0432.CCR-11-2109","article-title":"Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR\/KRAS and presence of PIK3CA\/AKT1 mutations","volume":"18","author":"Rekhtman","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0118","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/JTO.0b013e31824de0d6","article-title":"Brief report: a phase II \"window-of-opportunity\" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study","volume":"7","author":"Reungwetwattana","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0119","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217657","article-title":"EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2\/xL inhibition in non-small cell lung cancer","volume":"14","author":"Rice","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2022.101364_bib0120","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1535-7163.MCT-10-0792","article-title":"Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens","volume":"10","author":"Rivera","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2022.101364_bib0121","first-page":"1","article-title":"The PI3K\/Akt\/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles","volume":"237","author":"Sanaei","year":"2021","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.tranon.2022.101364_bib0122","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1586\/17512433.2015.1055252","article-title":"Strategies to overcome resistance to tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"8","author":"Santarpia","year":"2015","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.tranon.2022.101364_bib0123","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol. Cell"},{"key":"10.1016\/j.tranon.2022.101364_bib0124","doi-asserted-by":"crossref","first-page":"e30427","DOI":"10.1371\/journal.pone.0030427","article-title":"Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase","volume":"7","author":"Scrima","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2022.101364_bib0125","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00280-011-1788-4","article-title":"Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors","volume":"69","author":"Seki","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.tranon.2022.101364_bib0126","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature03794","article-title":"Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system","volume":"436","author":"Sengupta","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2022.101364_bib0127","doi-asserted-by":"crossref","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tranon.2022.101364_bib0128","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1158\/1078-0432.CCR-13-1777","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors","volume":"20","author":"Shapiro","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0129","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00018-010-0500-x","article-title":"Cigarette smoking reprograms apical junctional complex molecular architecture in the human airway epithelium in vivo","volume":"68","author":"Shaykhiev","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.tranon.2022.101364_bib0130","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317697568","article-title":"Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K\/Akt\/mTOR signaling pathway","volume":"39","author":"Shi","year":"2017","journal-title":"Tumor Biol."},{"key":"10.1016\/j.tranon.2022.101364_bib0131","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1038\/onc.2011.419","article-title":"TOPK\/PBK promotes cell migration via modulation of the PI3K\/PTEN\/AKT pathway and is associated with poor prognosis in lung cancer","volume":"31","author":"Shih","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2022.101364_bib0132","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1038\/s41388-018-0533-4","article-title":"IL-8-induced O-GlcNAc modification via GLUT3 and GFAT regulates cancer stem cell-like properties in colon and lung cancer cells","volume":"38","author":"Shimizu","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2022.101364_bib0133","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/1078-0432.CCR-11-2381","article-title":"The clinical effect of the dual-targeting strategy involving PI3K\/AKT\/mTOR and RAS\/MEK\/ERK pathways in patients with advanced cancer","volume":"18","author":"Shimizu","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0134","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.devcel.2008.12.006","article-title":"Great expectations for PIP: phosphoinositides as regulators of signaling during development and disease","volume":"16","author":"Skwarek","year":"2009","journal-title":"Dev. Cell"},{"key":"10.1016\/j.tranon.2022.101364_bib0135","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1634\/theoncologist.2014-0449","article-title":"Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors","volume":"20","author":"Soria","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2022.101364_bib0136","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1158\/0008-5472.CAN-08-4055","article-title":"PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR","volume":"69","author":"Sos","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0137","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1158\/1078-0432.CCR-12-2347","article-title":"Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models","volume":"18","author":"Spoerke","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CAD.0000000000000172","article-title":"New development of inhibitors targeting the PI3K\/AKT\/mTOR pathway in personalized treatment of non-small-cell lung cancer","volume":"26","author":"Sun","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.tranon.2022.101364_bib0139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CAD.0000000000000172","article-title":"New development of inhibitors targeting the PI3K\/AKT\/mTOR pathway in personalized treatment of non-small-cell lung cancer","volume":"26","author":"Sun","year":"2015","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.tranon.2022.101364_bib0140","series-title":"Blood Glucose Levels","article-title":"Role of PI3K\/AKT pathway in insulin-mediated glucose uptake","author":"\u015awiderska","year":"2018"},{"key":"10.1016\/j.tranon.2022.101364_bib0141","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1200\/jco.2013.31.15_suppl.8075","article-title":"Phase I study of ridaforolimus with cetuximab for patients with advanced non-small cell lung cancer (NSCLC), colorectal cancer, and head and neck cancer","volume":"31","author":"Taber","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0142","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/1759-7714.13328","article-title":"Targeting the PI3K\/Akt\/mTOR pathway in non-small cell lung cancer (NSCLC)","volume":"11","author":"Tan","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.tranon.2022.101364_bib0143","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2005.10.003","article-title":"Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis","volume":"51","author":"Tang","year":"2006","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2022.101364_bib0144","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.3892\/or.2017.5417","article-title":"Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation","volume":"37","author":"Tao","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.tranon.2022.101364_bib0145","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3389\/fgene.2019.00688","article-title":"MiR-486-5p serves as a good biomarker in NSCLC and suppresses cell growth with the involvement of a target-PIK3R1","volume":"10","author":"Tian","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.tranon.2022.101364_bib0146","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.biopha.2018.06.070","article-title":"Sirtuin 6 inhibits colon cancer progression by modulating PTEN\/AKT signaling","volume":"106","author":"Tian","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.tranon.2022.101364_bib0147","doi-asserted-by":"crossref","first-page":"e95303","DOI":"10.1371\/journal.pone.0095303","article-title":"Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease","volume":"9","author":"Toschi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2022.101364_bib0148","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/JTO.0000000000000663","article-title":"Introduction to the 2015 world health organization classification of tumors of the lung, pleura, thymus, and heart","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0149","doi-asserted-by":"crossref","first-page":"57733","DOI":"10.18632\/oncotarget.17496","article-title":"Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials","volume":"8","author":"Troncone","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2022.101364_bib0150","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1101\/gad.191973.112","article-title":"The p110\u03b1 and p110\u03b2 isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis","volume":"26","author":"Utermark","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.tranon.2022.101364_bib0151","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.lungcan.2017.01.011","article-title":"Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes","volume":"106","author":"VanderLaan","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2022.101364_bib0152","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.radonc.2006.07.032","article-title":"Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours","volume":"80","author":"Vink","year":"2006","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0153","series-title":"Proceedings of the American Association for Cancer Research Annual Meeting","article-title":"Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinositide-3-kinase in phase I\/II trials","author":"Voliva","year":"2010"},{"key":"10.1016\/j.tranon.2022.101364_bib0154","doi-asserted-by":"crossref","first-page":"e71533","DOI":"10.1371\/journal.pone.0071533","article-title":"Ets2 in tumor fibroblasts promotes angiogenesis in breast cancer","volume":"8","author":"Wallace","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2022.101364_bib0155","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1158\/1535-7163.MCT-11-0446","article-title":"GDC-0980 is a novel class I PI3K\/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway","volume":"10","author":"Wallin","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2022.101364_bib0156","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-016-0399-7","article-title":"Hyperthermia induced HIF-1a expression of lung cancer through AKT and ERK signaling pathways","volume":"35","author":"Wan","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0157","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cbf.3278","article-title":"Fractalkine\/CX3CR1 induces apoptosis resistance and proliferation through the activation of the AKT\/NF-\u03baB cascade in pancreatic cancer cells","volume":"35","author":"Wang","year":"2017","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.tranon.2022.101364_bib0158","doi-asserted-by":"crossref","first-page":"e88291","DOI":"10.1371\/journal.pone.0088291","article-title":"PIK3CA mutations frequently coexist with EGFR\/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR\/KRAS wildtype subgroup","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2022.101364_bib0159","article-title":"Clinical significance of PIK3CA gene in non-small-cell lung cancer: a systematic review and meta-analysis","volume":"2020","author":"Wang","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.tranon.2022.101364_bib0160","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000442147","article-title":"A phase I trial of temsirolimus and pemetrexed in patients with advanced non-small cell lung cancer","volume":"61","author":"Waqar","year":"2016","journal-title":"Chemotherapy"},{"key":"10.1016\/j.tranon.2022.101364_bib0161","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000348584","article-title":"A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer","volume":"59","author":"Waqar","year":"2013","journal-title":"Chemotherapy"},{"key":"10.1016\/j.tranon.2022.101364_bib0162","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1172\/JCI200316147","article-title":"Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells","volume":"111","author":"West","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tranon.2022.101364_bib0163","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11523-017-0482-9","article-title":"A phase Ib study of the dual PI3K\/mTOR inhibitor dactolisib (BEZ235) combined with everolimus in patients with advanced solid malignancies","volume":"12","author":"Wise-Draper","year":"2017","journal-title":"Target. Oncol."},{"key":"10.1016\/j.tranon.2022.101364_bib0164","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/CEJ.0000000000000214","article-title":"Gene expression profiling of lung adenocarcinoma in Xuanwei, China","volume":"25","author":"Wu","year":"2016","journal-title":"Eur. J. Cancer Prev."},{"key":"10.1016\/j.tranon.2022.101364_bib0165","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1128\/MCB.16.4.1722","article-title":"Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction","volume":"16","author":"Wymann","year":"1996","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.tranon.2022.101364_bib0166","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13578-020-00416-0","article-title":"Roles of the PI3K\/AKT\/mTOR signalling pathways in neurodegenerative diseases and tumours","volume":"10","author":"Xu","year":"2020","journal-title":"Cell Biosci."},{"key":"10.1016\/j.tranon.2022.101364_bib0167","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.bbcan.2014.10.007","article-title":"mTOR signaling in tumorigenesis","volume":"1846","author":"Xu","year":"2014","journal-title":"Biochim. Biophys. Acta (BBA) Rev. Cancer"},{"key":"10.1016\/j.tranon.2022.101364_bib0168","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/19336918.2015.1016686","article-title":"A new role for the PI3K\/Akt signaling pathway in the epithelial-mesenchymal transition","volume":"9","author":"Xu","year":"2015","journal-title":"Cell Adhes. Migr."},{"key":"10.1016\/j.tranon.2022.101364_bib0169","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1756-9966-30-33","article-title":"Osthole induces G2\/M arrest and apoptosis in lung cancer A549 cells by modulating PI3K\/Akt pathway","volume":"30","author":"Xu","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0170","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1158\/0008-5472.CAN-10-0043","article-title":"Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations","volume":"70","author":"Yamamoto","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0171","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/OTT.S225010","article-title":"miR-1269b drives cisplatin resistance of human non-small cell lung cancer via modulating the PTEN\/PI3K\/AKT signaling pathway","volume":"13","author":"Yang","year":"2020","journal-title":"OncoTarget. Ther."},{"key":"10.1016\/j.tranon.2022.101364_bib0172","doi-asserted-by":"crossref","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0173","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.bpj.2017.09.008","article-title":"Phosphorylated calmodulin promotes PI3K activation by binding to the SH2 domains","volume":"113","author":"Zhang","year":"2017","journal-title":"Biophys. J."},{"key":"10.1016\/j.tranon.2022.101364_bib0174","doi-asserted-by":"crossref","first-page":"5333","DOI":"10.2147\/CMAR.S204358","article-title":"Gephyrin suppresses lung squamous cell carcinoma development by reducing mTOR pathway activation","volume":"11","author":"Zhang","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.tranon.2022.101364_bib0175","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20182443","article-title":"Nicotine promotes the development of non-small cell lung cancer through activating LINC00460 and PI3K\/Akt signaling","volume":"39","author":"Zhao","year":"2019","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.tranon.2022.101364_bib0176","first-page":"3233","article-title":"Prognostic value of KRAS\/TP53\/PIK3CA in non-small cell lung cancer","volume":"17","author":"Zhao","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.tranon.2022.101364_bib0177","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1159\/000488831","article-title":"Effect of miR-21 on apoptosis in lung cancer cell through inhibiting the PI3K\/Akt\/NF-\u03baB signaling pathway in Vitro and in Vivo","volume":"46","author":"Zhou","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.tranon.2022.101364_bib0178","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3390\/ijms13022025","article-title":"Bufalin induces lung cancer cell apoptosis via the inhibition of PI3K\/Akt pathway","volume":"13","author":"Zhu","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2022.101364_bib0179","first-page":"503","article-title":"The novel dual PI3K\/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells","volume":"5","author":"Zou","year":"2012","journal-title":"Mol. Med. Rep."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523322000262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523322000262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:21:23Z","timestamp":1761844883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523322000262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":179,"alternative-id":["S1936523322000262"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2022.101364","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The PI3K\/Akt\/mTOR pathway in lung cancer; oncogenic alterations, therapeutic opportunities, challenges, and a glance at the application of nanoparticles","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2022.101364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101364"}}